Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT01166854

Conditions

Muscle Disorder

Bone Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Diffuse Optical Spectroscopy

Study Details

Brief summary:

The researcher wants to explore the genetic causes of muscle disease. The researcher is particularly interested in muscle disorders that occur in combination with diseases of bone that appear to be passed on from generation to generation.

Diffuse Optical Spectroscopy will measure the concentrations of blood, water, and lipids (fats, for example) in your tissues. This device essentially measures the color of tissues in order to determine tissue physiology (its physical and chemical processes).

Conditions

Muscle Disorder

Bone Disorder

Study ID

NCT01166854

Start date

Jun 18, 2010

Status verified date

Jun, 2025

Completion date

Jun, 2030

Anticipated

Primary completion date

Jun, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria: Male or Female age 18 and older

  • diagnose of Muscle or bone disorders
  • with a combination of medical problems including muscle and bone disease and their family members.

Exclusion Criteria:

  • under 18 year of age
  • unrelated diagnosis

Study Design

Enrollment

25 participants

Anticipated

Interventions and Outcome Measures

Arms

Muscle weakness

Diffuse Optical Spectroscopy

Interventions

Diffuse Optical Spectroscopy

Diffuse Optical Spectroscopy

Primary outcome measure

  • muscle disease [ Time Frame: 1 week ]

Central Contacts and Locations

Central contacts

Locations

Hewitt Hall

Recruiting

Irvine, California, United States, 92697

Contacts

More Information

Sponsor

University of California, Irvine

Last update posted

Jun 18, 2025

Last verified

Jun, 2025

Keywords

  • muscle and bone disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2025-06-18.